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Abstract
After an inflammatory stimulus, lymphocyte migration into draining lymph nodes increases
dramatically to facilitate the encounter of naïve T cells with antigen-loaded dendritic cells. Here we
show that CD73 (ecto-5′-nucleotidase) plays an important role in regulating this process. CD73
produces adenosine from AMP and is expressed on high endothelial venules (HEV) and subsets of
lymphocytes. Cd73-/- mice have normal sized lymphoid organs in the steady state, but approximately
1.5-fold larger draining lymph nodes and 2.5-fold increased rates of L-selectin-dependent
lymphocyte migration from the blood through HEV compared to wild type mice 24 hours after LPS
administration. Migration rates of cd73+/+ and cd73-/- lymphocytes into lymph nodes of wild type
mice are equal, suggesting that it is CD73 on HEV that regulates lymphocyte migration into draining
lymph nodes. The A2B receptor is a likely target of CD73-generated adenosine, as it is the only
adenosine receptor expressed on the HEV-like cell line KOP2.16 and it is up regulated by TNFα.
Furthermore, increased lymphocyte migration into draining lymph nodes of cd73-/- mice is largely
normalized by pretreatment with the selective A2B receptor agonist BAY 60-6583. Adenosine
receptor signaling to restrict lymphocyte migration across HEV may be an important mechanism to
control the magnitude of an inflammatory response.
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INTRODUCTION
Lymphocyte circulation from the blood stream to lymph nodes is necessary for immune
homeostasis (reconnaissance) under normal physiological conditions and for immune
responses against exogenous antigens. This trafficking requires coordinated action of adhesion
molecules, chemokines, and chemokine receptors expressed on lymphocytes and high
endothelial venules (HEV4) (reviewed in 1 and 2). The interaction of L-selectin with peripheral
lymph node addressins (PNAd) initiates lymphocyte tethering and rolling on HEV (3).
Chemokine receptor signaling activates the integrin LFA-1 on lymphocytes and induces stable
adhesion via binding to ICAM-1 on HEV (4,5) which is followed by transmigration. The
importance of each molecule associated with the entrance of lymphocytes into lymph nodes
through HEV has been shown by decreases in lymph node cellularity and defective immune
responses in gene-targeted mice (6-10).
TLR signaling activates innate immune responses (reviewed in 11) in part by inducing APC
maturation and recruitment to lymphoid organs via the afferent lymphatics (12,13).
Furthermore, recent reports showed that inflammation induced by a TLR 4 or 9 agonist
controlled naïve lymphocyte recirculation in an antigen-independent manner, resulting in an
increase in the number of naïve lymphocytes in the draining lymph node and an increase in the
efficiency of lymphocyte-APC encounters (14). TLR-dependent lymph node hypertrophy was
proposed to require vascular growth and arteriole thickening. Although these changes needed
at least a few days before they were detectible (14,15), lymph node growth began within 24 h
after a stimulus, implying the existence of other mechanisms that contribute to lymph node
swelling. Here we present data to show that adenosine (Ado) receptor signaling, mediated by
CD73-generated Ado, plays an important role in regulating early migration of lymphocytes to
draining lymph nodes.
CD73 is a 70-kDa glycosyl phosphatidylinositol (GPI)-anchored protein with ecto-5′-
nucleotidase enzyme activity that catalyzes the dephosphorylation of extracellular nucleoside
monophosphates such as AMP to nucleosides such as Ado (16). Extracellular Ado can engage
four subtypes of ubiquitously expressed Ado receptors (A1AR, A2AAR, A2BAR and A3AR)
to modulate a wide array of physiological responses including vascular tone,
neurotransmission, cytokine production, heart rate, and adaptation to hypoxia (reviewed in
17). In addition to being generated by CD73, Ado can also be generated intracellularly through
the action of cytoplasmic nucleotidases and then exported via nucleoside transporters.
Extracellular Ado has a very short half-life, as it is efficiently taken up into the cytoplasm
where it can be phosphorylated to AMP or degraded to inosine by adenosine deaminase (ADA).
In humans, ADA can be localized to the cell surface via binding to CD26 (18,19), giving it the
potential to inhibit Ado receptor signaling through deamination of extracellular Ado (20). Mice
deficient in the expression of each Ado receptor have been engineered and characterized
(21-25). Each strain has a variety of interesting phenotypes, revealing the diverse consequences
of Ado receptor signaling. However, the mechanism by which extracellular Ado levels are
regulated to modulate Ado receptor engagement in vivo is not fully understood.
4Abbreviations used: Ado, adenosine; ADA, adenosine deaminase; AR, adenosine receptor; CFMDA, 5-chloromethylfluorescein
diacetate; CMTMR, 5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine); DC, dendritic cell; GPI, glycosyl phosphatidyl
inositol; HEV, high endothelial venule; PEG, polyethylene glycol; PNAd, peripheral lymph node addressin.
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Ado is a well-known anti-inflammatory mediator (26). Recent studies clearly showed that
CD73 makes a major contribution to the generation of extracellular Ado in a number of
physiologically relevant experimental models and plays a critical role in host defense systems.
For example, CD73 attenuates hypoxia-induced vascular leakage, FMLP-stimulated neutrophil
adhesion to endothelial cells, and neutrophil accumulation in tissues (27-29). Furthermore,
cd73-deficient mice are susceptible to vascular inflammation and neointima formation due to
decreased concentrations of endogenous Ado (30). CD73 deficiency increases VCAM-1
expression on endothelial cells isolated from carotid arteries through NF-κB activation;
however, ICAM-1 expression is unchanged. This pro-inflammatory phenotype of cd73-
deficient endothelium causes the arrest of monocytes and exacerbates wire-induced injury.
These observations demonstrated a crucial role for CD73-generated Ado in the interaction of
myeloid cells with vascular endothelium. However, the in vivo function of this molecule in
lymphocyte-endothelium crosstalk remains unclear. In addition to its enzymatic role in the
production of extracellular Ado, CD73 has also been characterized as a signaling molecule
(31) and an adhesion molecule (32). Engagement of lymphocyte CD73 with anti-CD73 mAbs
has been shown to stimulate proliferation, IL-2 secretion and IL-2R expression (33,34).
Furthermore, blocking this molecule on lymphocytes with an antibody appears to inhibit
adhesion of lymphocytes to cultured endothelial cells (35). Thus, there are multiple
mechanisms by which CD73 could impact lymphocyte migration across HEV. We show here
that cd73-deficient mice have increased rates of lymphocyte homing to draining lymph nodes
and propose that CD73-generated Ado regulates the ability of lymphocytes to migrate across
HEV, thus limiting their access to inflamed lymph nodes.
MATERIALS AND METHODS
Mice
Cd73-deficient mice developed in our laboratory (27) were backcrossed onto C57BL/6J for 14
generations. Genotyping by PCR, using primers that differentiate between the wild type
cd73 allele and the mutated cd73 allele containing a neomycin resistance cassette, was
performed as previously described. A2BAR-/- mice were obtained from Deltagen (San Mateo,
CA) and have also been backcrossed onto the C57BL/6 background. All mice were bred and
maintained in our animal facility under specific pathogen-free conditions. All protocols were
approved by the Oklahoma Medical Research Foundation Institutional Animal Care and Use
Committee.
Cell culture
The cell line KOP2.16 was derived from stromal cells taken from pooled mouse lymph nodes
and has been described previously (36). It was cultured in DMEM supplemented with 20%
FCS (Hyclone), 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 5 × 10-5 M 2-
ME, non-essential amino acids, 100 U/ml penicillin, and 100 μg/ml streptomycin. In some
experiments, 20 ng/ml TNFα (R&D Systems) was added for 3 to 6 h.
Cd73 and adenosine receptor gene expression
Cd73 and Ado receptor expression were analyzed by PCR in a full length cDNA library derived
from MACS® (Miltenyi Biotec)-isolated PNAd+ endothelial cells from lymph nodes (37) using
previously described primers (38). In other experiments, RNA was prepared from KOP2.16
and RT-PCR was performed as described using β-actin as an internal control (38).
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Digestion of lymph nodes for characterization of HEV or enumeration of CD11c+ dendritic
cells by flow cytometry
Lymph nodes were dissected from mice, minced with scissors and digested in RPMI 1640
containing 10% FCS, 1 mg/ml collagenase B (Roche) and 2 μg/ml DNase I (Roche) for 30 min
at 37°C with shaking at 50 rpm. The cell suspension was passed through a Pasteur pipette 40
times followed by digestion with 0.2% trypsin (Cellgro) and 0.5 mM EDTA at 37°C for 10
min. Cells were then passed through a 70-μm filter, washed, and stained.
Immunofluorescence
Lymphoid cells or PNAd+ cells were stained with the following monoclonal antibodies: FITC
anti-CD4, FITC anti-CD8, FITC anti-MHC Class II, PE anti-CD11c, PE Cy5.5 anti-CD19 and
allophycocyanin anti-CD45R (Caltag); PE anti-TCRβ (BD Pharmingen); allophycocyanin
anti-CD45 (Southern Biotech), and biotinylated anti-CD73 (TY/23) (39), according to standard
methods. PE-streptavidin was from BD Pharmingen. Data were collected with a FACSCalibur
(Becton-Dickinson) and analyzed with CellQuest software. For lymphocyte migration
experiments and experiments to enumerate DCs, data were collected on 750,000 and 350,000
cells, respectively.
Immunohistochemistry
Frozen sections (7 μm) of lymph nodes were fixed with cold acetone and blocked with 3%
BSA in PBS. Sections were stained with TY/23 (anti-CD73, IgG2a) followed by Alexa Fluor
488 conjugated donkey anti-rat IgG (Molecular Probes) and then blocked with purified mouse
IgG at 500 μg/ml. After washing, they were then stained with either Alexa Fluor 594 conjugated
anti-PNAd mAb MECA-79 (IgM, BD Pharmingen). Other slides were stained with a
combination of TY/23 and rabbit anti-collagen IV (Chemicon) followed by a combination of
Alexa Fluor 488 conjugated donkey anti-rat IgG plus Alexa Fluor 594 conjugated donkey anti-
rabbit IgG (Molecular Probes).
Inflammatory stimuli
Anesthetized mice were injected with 1 μg E. coli LPS (055:B5, Sigma-Aldrich) or 5 μg poly
(I:C) (Sigma-Aldrich) in 30 μl PBS in the left front footpad using an insulin syringe. The right
footpad was injected with same volume of PBS. Twenty-four hours later, brachial lymph nodes
were examined as draining lymph nodes. In other experiments, mice were injected in either
the rear footpad or thigh and popliteal or inguinal lymph nodes, respectively, were studied as
draining lymph nodes.
Lymphocyte homing assay
Total splenocytes were labeled with 0.25 μM 5-chloromethylfluorescein diacetate (CMFDA,
Molecular Probes) for 30 min at 37°C. Ten million labeled cells were injected i.v. into mice
and one h later, spleen and lymph nodes were harvested. In some experiments, cd73-deficient
and wild type splenocytes were labeled with 0.25 μM CMFDA and 2 μM 5-(and-6)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine) (CMTMR, Molecular Probes),
respectively, for 30 min at 37°C. Equal numbers of labeled cells were co-injected i.v. into both
strains of mice. Harvested lymph nodes were pushed through 70-μm filters to make single cell
suspensions. Cells were then counted and the percentages of labeled cells were determined by
flow cytometry. In selected experiments, anti-L-selectin antibody (MEL-14, Southern Biotech)
was given to mice (50 μg/mouse i.v.) simultaneously with LPS. In other experiments, mice
were pre-treated with the A2BAR agonist BAY 60-6583 (40) at 0.32 mg/kg (Bayer HealthCare,
Wuppertal, Germany, dissolved in polyethylene glycol (PEG) 400 and diluted to 80 μg/ml in
PBS for i.v. injection) 30 min prior to the injection of labeled splenocytes.
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RESULTS
CD73 and Ado receptor expression in lymphoid tissues and HEV
We previously reported the expression pattern of CD73 in lymphoid tissues of BALB/c mice
(39); however, experiments indicating that CD73 expression was strain-dependent prompted
us to investigate CD73 expression in lymphoid cells of C57BL/6 mice prior to using this strain
for the experiments described in this report. Staining with monoclonal antibody TY/23 revealed
that approximately 50% of CD4+, 85% of CD8+ and 2% of CD19+ lymphocytes derived from
lymph nodes of wild type mice expressed CD73 (Fig. 1A). We confirmed the findings of Kobie
et al. (41) that CD73 is expressed on CD4+CD25+Foxp3+ regulatory T cells. Nevertheless,
cd73+/+ and cd73-/- mice had similar proportions of T cells with this phenotype (data not
shown). Lymphocytes from cd73-/- mice expressed no detectable CD73, confirming the
deletion. We also analyzed CD73 expression on HEV by flow cytometry, gating on the rare
population of CD45- PNAd+ cells (0.05-0.15% of cells from enzyme-digested whole lymph
nodes). Relatively high CD73 expression was observed on HEV compared to lymphocytes
(Fig. 1B). In order to substantiate the results, immunohistochemistry was performed (Fig.
1C). Sections stained with anti-PNAd antibody and TY/23 revealed that HEV expressed CD73
abundantly. In contrast, only a few lymphocytes expressed enough CD73 to be detectable by
this method. In addition, double staining with anti-collagen IV antibody and TY/23
demonstrated that CD73 is also expressed homogenously on basal lamina (i.e., not polarized
to the luminal or abluminal surface).
Steady-state mRNA levels of cd73 and the Ado receptors were measured in HEV by PCR,
using a cDNA library derived from PNAd+ endothelial cells (Fig. 1D). Cd73 and A2BAR were
detected, but A1AR, A2AAR and A3AR were not expressed at detectible levels. Steady-state
levels of Ado receptor mRNA in murine splenocytes are shown in Fig. 1E. All Ado receptors
except the A1AR were easily detected.
Cd73-deficient mice have large draining lymph nodes
CD73 has been proposed to modulate lymphocyte-endothelial cell interactions as an adhesion
molecule (32,35). Therefore, we asked whether CD73 plays a role in lymphocyte homing to
secondary lymphoid tissue in the steady state. The sizes of spleen, peripheral lymph nodes,
Peyer’s patches and mesenteric lymph nodes in cd73-deficient mice were normal (27 and
unpublished data). Furthermore, the migration of CMFDA-labeled cd73-/- splenocytes to
lymphoid tissues (spleen and lymph node) of unmanipulated cd73-/- mice was also comparable
to that of cd73+/+ splenocytes to lymphoid organs of unmanipulated wild type mice
(unpublished data). These observations suggested that CD73 does not have an obvious function
in lymphocyte homing under steady state conditions.
CD73 plays important roles in vivo in maintaining the integrity of the vascular endothelium
during hypoxia (27-29) and in regulating endothelial adhesion molecule expression after wire-
induced injury (30). Taking this information into account, and considering the well-known
anti-inflammatory properties of Ado, we hypothesized that CD73 might also regulate
lymphocyte-HEV interactions after an inflammatory stimulus. To address this issue, LPS was
injected into front left footpads of cd73+/+ and cd73-/- mice and 24 h later, the brachial
(draining) lymph node cellularity was examined (Fig. 2A). The same volume of PBS was
administered to the contralateral side as a control. As expected from previous studies (14,15),
the draining lymph nodes were dramatically enlarged compared to those on the control side in
wild type mice. Consistent with our hypothesis, there was a further increase in the size of the
draining lymph nodes from cd73-deficient mice, which were approximately 1.5-fold larger
than those of wild type mice. To examine whether lymphocyte migration from the blood stream
to lymph nodes is also accelerated in cd73-/- mice, CMFDA-labeled wild type splenocytes were
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injected i.v. 24 h after LPS injection and the accumulation of labeled cells in the lymph nodes
was measured after 1 h by flow cytometry (Fig. 2B). Although no differences were observed
between cd73+/+ and cd73-/- mice on the control side, the number of lymphocytes that migrated
into the draining lymph nodes of cd73-deficient mice was 2.7-fold greater than in wild type
mice. These results suggest that it is CD73 on HEV (rather than on lymphocytes) that is
responsible for the larger sizes of draining lymph nodes in cd73-deficient mice. Similar results
were seen when poly(I:C), a TLR3 ligand, was used instead of LPS as the inflammatory
stimulus (Fig. 2C,D). Furthermore, staining with TCRβ (Fig. 2E) and B220 (Fig. 2F) antibodies
revealed that migration of both T and B lymphocytes was increased in cd73-deficient draining
lymph nodes. Similar results were observed when LPS or poly(I:C) were injected into the rear
footpad or thigh as revealed by examination of popliteal or inguinal lymph nodes, respectively
(unpublished data).
Next, we asked whether the increased lymphocyte migration and enlarged lymph nodes seen
in cd73-deficient mice were the result of increased migration across HEV. To address this
question, mice were pre-treated with L-selectin antibody. This antibody was chosen because
lymphocyte expressed L-selectin is known to initiate rolling on HEV (through its interaction
with PNAd) and because administration of L-selectin antibody has been shown to diminish
lymphocyte migration to peripheral lymph nodes under steady state conditions in vivo (3,42).
We observed that treatment of mice with L-selectin antibody i.v. at the same time as LPS,
abrogated CMFDA-labeled lymphocyte migration even after 24 h in both strains of mice (Fig.
2H) and abolished the hallmark increased size of cd73-deficient draining lymph nodes (Fig.
2G).
Contribution of lymphocyte CD73 expression to migration across HEV
Because lymphocyte CD73 has been reported to be a signaling molecule, an adhesion molecule,
and a maturation and subpopulation marker (16,39), we next evaluated its role in lymphocyte
migration into draining lymph nodes. We first examined the percentage of CD4+, CD8+, and
CD19+ lymphocytes that co-expressed CD73 in wild type draining lymph nodes by flow
cytometry 24 h after stimulation. LPS-induced lymph node hypertrophy did not affect the CD73
expression pattern compared with that in lymph nodes from the PBS-treated side (Fig. 3A).
The CD73 expression pattern was also equivalent to that in naïve lymph nodes and spleen
(unpublished data). We next evaluated migration of cd73-deficient lymphocytes compared to
wild type lymphocytes in both wild type and cd73-deficient mice. This was done by injecting
mice with a 1:1 mixture of splenocytes from cd73+/+ and cd73-/- mice labeled with either
CMFDA or CMTMR. Virtually identical ratios of cd73-/-:cd73+/+ lymphocytes were observed
in both wild type and cd73-deficient draining lymph nodes (Fig. 3B). These results suggest no
bias between CD73 positive and negative lymphocytes in their ability to migrate after an
inflammatory stimulus. They further suggest that it is a lack of CD73 expression on HEV that
is responsible for the increased migration of lymphocytes into draining lymph nodes of cd73-
deficient mice.
Contribution of DC to increased draining lymph node size in cd73-/- mice
The accumulation of activated DC in draining lymph nodes is critical for the regulation of pro-
inflammatory cytokine production and induction of vascular growth (15). Local injection of
LPS is known to induce DC migration to draining lymph nodes through the lymphatics and
also their maturation and cytokine production (13). As previous reports showed that Ado is
one of the key regulators of DC function (43,44), we speculated that the hypertrophied draining
lymph nodes in cd73-/- mice might be due to increased migration of DCs though the lymphatics.
Therefore, we measured the absolute numbers of MHC Class IIhi CD11c+ DCs in the draining
lymph nodes of wild type and cd73-/- mice 6 h after the injection of LPS (Fig.4A). As expected,
the numbers of DCs were increased in the draining lymph nodes of both strains of mice
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compared to those on the contralateral side. There was a trend towards higher numbers of DCs
in the draining lymph nodes of cd73-/- mice, as the average number was almost 50% higher
than for wild type mice; however, this difference was not statistically significant (p=0.14).
Nevertheless, these data suggest that increased cytokine production by DC could contribute to
the larger size of draining lymph nodes in cd73-/- mice. It is interesting to note that the draining
lymph nodes in the cd73-/- mice were significantly larger than those of wild type mice (p=0.034)
even at this early time point (Fig. 4B), suggesting that the kinetics of the inflammatory response
are accelerated when CD73 is absent.
Up regulation of cd73 and A2BAR on HEV after an inflammatory stimulus
Previous studies showed CD73 expression can be regulated on HUVEC by mediators that are
released during an inflammatory response, such as TNFα (45), IFNα (46), and Ado (47). Flow
cytometry revealed a slight up regulation of cell surface CD73 on CD45-PNAd+ cells in
draining lymph nodes relative to its level on HEV from control lymph nodes (Fig. 5A). Due to
the lack of specific Ado receptor antibodies suitable for flow cytometry, we used KOP2.16, a
cell line derived from lymph node endothelial cells, and semi-quantitative RT-PCR to examine
the regulation of Ado receptor expression. Similar to what we observed in the HEV cDNA
library (Fig. 1D), KOP2.16 expressed only the A2BAR. Expression increased 3- to 5-fold 3 h
after TNFα stimulation in two independent experiments (Fig. 5B). These results suggest that
elevated Ado, known to occur at sites of inflammation, could trigger the A2BAR on HEV in
draining lymph nodes and that this could play a role in regulating lymphocyte migration into
these nodes.
Adenosine receptor stimulation inhibits the increased lymphocyte migration into draining
lymph nodes of cd73-deficient mice
Our previous findings and those of others suggest that Ado generated extracellularly by CD73
can modulate endothelial cell adhesion molecule expression and permeability via the A2AAR
and A2BAR (27-30). Based on these findings, and our own observation that the A2BR was the
only Ado receptor expressed on HEV, we asked whether the A2BAR-specific agonist BAY
60-6583 could influence lymphocyte homing after an inflammatory stimulus. As shown in Fig.
6A, treatment with BAY 60-6583 markedly decreased (p=0.0034) the number of lymphocytes
that migrated into the draining lymph nodes of CD73-deficient mice. There was no impact on
lymphocyte migration into lymph nodes on the contralateral side. The effect of BAY 60-6583
on lymphocyte migration into draining lymph nodes of wild type mice was much more modest
and did not reach statistical significance (data not shown), perhaps because of higher
concentrations of endogenous adenosine in these mice. All of these results support our
hypothesis that CD73-generated Ado serves to regulate lymphocyte migration into draining
lymph nodes after an inflammatory stimulus at least in part by triggering A2BAR signaling on
HEV. Consistent with this hypothesis, A2BAR+/+ and A2BAR-/- lymphocytes showed equivalent
rates of lymphocyte migration into draining lymph nodes of LPS-treated wild type and
cd73-/- mice (Fig. 6B).
DISCUSSION
Lymphocyte homing to peripheral lymph nodes depends on interactions with HEV, specialized
blood vessels that express chemokines and adhesion molecules required for lymphocyte
transmigration. Although numerous reports have demonstrated the importance of L-selectin,
PNAd, LFA-1, ICAM-1, and specific chemokines and chemokine receptors in the steady state,
the way in which lymphocyte migration across HEV is regulated during an inflammatory
response is not fully understood. The goal of this investigation was to determine if CD73, which
is expressed on both PNAd+ endothelial cells and the basal lamina comprising HEV, plays a
role in this process. The source of CD73 expressed on basal lamina is not known. However,
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CD73 is a GPI-anchored protein and previous studies by Mehul et al. (48) showed that CD73
can bind to laminin, one of the components of the basal lamina. Therefore, we hypothesize that
CD73 may be synthesized in cells such as endothelial cells, cleaved from the cell surface by a
phospholipase, and then bind to a component of the basal lamina such as laminin.
The contribution of CD73 to the formation of extracellular Ado, a well-known anti-
inflammatory mediator, has been revealed in several experimental models. For example, the
anti-inflammatory action of methotrexate in the carrageenan-treated air pouch model of
inflammation is dependent upon CD73 (49). Similarly, CD73-generated Ado is necessary for
ischemic preconditioning in both the heart (40) and kidney (50), and protects mice from
bleomycin-induced lung injury (51). Furthermore, cd73-deficient mice exhibit a vascular leak
syndrome characterized by neutrophil infiltration into tissues when exposed to normobaric
hypoxia, suggesting a critical role for CD73-generated Ado in vascular barrier function
(27-29). On the other hand, several in vitro studies suggested that CD73 functions as a
costimulatory molecule on T lymphocytes (33,34) and an adhesion molecule that is important
for lymphocyte binding to endothelium (35). The possibility that CD73 could impact
lymphocyte interactions with HEV by multiple mechanisms prompted us to examine the role
of this molecule in lymphocyte homing to lymph nodes. We showed here that Ado generated
by CD73 on HEV negatively regulates lymphocyte migration from the blood stream into LPS-
induced draining lymph nodes. As cd73+/+ and cd73-/- splenocytes showed equivalent rates of
migration into draining lymph nodes, it is unlikely that any signaling or adhesive function of
CD73 on lymphocytes plays a role in regulating migration of lymphocytes across HEV.
Although no abnormalities were observed in the cellularity of lymphoid organs of cd73-/- mice
or in the migratory capacity of cd73-/- lymphocytes under steady state conditions, cd73-/- mice
had larger draining lymph nodes when LPS, a TLR 4 agonist, was injected into a local site.
Short term assays with CFMDA-labeled lymphocytes administered i.v., showed increased rates
of migration into the draining lymph nodes of cd73-/- mice. This observation, coupled with the
forward vs. side scatter profile of the lymphocytes (unpublished data), suggested that the lymph
node hypertrophy induced by LPS was not due to the proliferation of lymphocytes, but rather
to the accumulation of non-dividing lymphocytes. Furthermore, anti-L-selectin antibody
treatment demonstrated that CD73 modulates lymphocyte migration into draining lymph nodes
by an L-selectin-dependent pathway. Interestingly, both T and B lymphocyte entrance was
promoted in cd73-/- mice, suggesting that a common pathway for both cell types is modulated
by CD73. In addition, the percentages of CD73+ and CD73- lymphocytes did not change when
splenocytes from cd73+/+ mice were used as donors in migration experiments in cd73+/+ mice,
indicating that the ability to migrate across HEV was not influenced by the CD73 expression
status of lymphocytes. Furthermore, the migration of splenocytes from cd73+/+ and cd73-/-
mice into draining lymph nodes of cd73-/- mice was comparable, demonstrating that CD73
expression on lymphocytes cannot compensate for a lack of CD73 on HEV.
Information in the literature concerning the regulation of endothelial CD73 expression by pro-
inflammatory cytokines is conflicting. For example, Kalsi et al. (45) showed a decrease in its
expression and in its enzyme activity after TNFα treatment of HUVEC. On the other hand,
Niemela and co-workers demonstrated that IFNα and IFNγ, but not other inflammatory
cytokines such as IL-1β, IL-4, or TNFα could increase CD73 expression on HUVEC (46).
Furthermore, Ado has been implicated in an increase in CD73 expression in microvascular
endothelial cells that is mediated by a paracrine pathway (47). Our experiments revealed that
the expression of CD73 on HEV in draining lymph nodes is up regulated compared to HEV
in the contralateral side. Although our analysis has the advantage of evaluating changes in
CD73 expression in vivo, the mechanism by which CD73 expression is modulated is still
unknown.
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To determine whether the enhanced lymphocyte migration in cd73-deficient mice was caused
by a lack of Ado receptor signaling, we treated mice with the A2BR agonist BAY 60-6583.
This approach was taken because of the four known subtypes of Ado receptors, only the
A2BAR was found in a cDNA library derived from PNAd+ cells or in cDNA from the HEV-
like cell line KOP2.16 (36). We also observed an up regulation of A2BAR expression in
KOP2.16 cells after exposure to TNFα. Indeed, BAY 60-6583 treatment markedly reduced the
rate of migration of labeled splenocytes into draining lymph nodes of cd73-/- mice. These data
are consistent with the hypothesis that the A2BAR is at least partially responsible for the
regulation of lymphocyte migration across HEV by CD73-generated Ado. Furthermore, the
Ado is likely derived from CD73 on HEV, as lymphocytes from cd73+/+ and cd73-/- mice show
similar increased rates of migration across HEV in draining lymph nodes of cd73-/- mice (i.e.,
Ado produced by cd73+/+ lymphocytes does not appear able to trigger adenosine receptors on
HEV to regulate lymphocyte migration). Similarly, lymphocytes from A2BR+/+and A2BR-/-
mice showed similar rates of migration into draining lymph nodes of wild type mice, suggesting
that it is triggering of the A2BR on HEV that is relevant.
The expression of the adhesion molecules ICAM-1 and VCAM-1 is normal on cd73-/- HEV
in the steady state (unpublished data). Our findings differ from those in a previous report
(30) which concluded that CD73 deficiency resulted in increased VCAM-1 expression and
decreased ICAM-1 expression on carotid arteries due to the lack of A2AAR signaling. This
discrepancy could be explained by the fact that different cell types were being examined and
that the A2BAR, rather than the A2AAR, seems to be the predominant AR on HEV. We did
find that VCAM-1, but not ICAM-1, expression was up regulated on HEV in draining lymph
nodes after LPS administration and this effect was more pronounced in cd73-/- mice. However,
neither anti-VLA-4 nor anti-VCAM-1 antibody treatment reversed the increased rates of
lymphocyte migration into draining lymph nodes of cd73-/- mice after LPS treatment
(unpublished data), suggesting that the increase in VCAM-1 expression did not augment cell
adhesion between lymphocytes and HEV. Furthermore, although the migration of CMFDA-
labeled lymphocytes to draining lymph nodes was inhibited by treatment with an anti-LFA-1
antibody, the effect was the same in both cd73+/+ and cd73-/- mice (unpublished data). Taken
together, these data support the conclusion that increased lymphocyte migration into draining
lymph nodes of cd73-deficient mice is not mediated by increases in cell adhesion.
We propose instead that Ado generated by endothelial cell (and/or basal lamina) CD73
regulates lymphocyte migration across HEV through A2BAR signaling. The A2BAR is a seven
transmembrane-spanning G protein-coupled receptor that is coupled to Gs and uses cAMP as
a second messenger (52). It has been firmly established that cAMP can modulate endothelial
cell-cell junctions through the protein kinase A and/or Epac-Rap1 pathways (53,54). Other
reports suggest that the A2BAR can also be coupled to Gq (55). In the 1970s, several studies
concluded that lymph node vasculature changed within 24 h after an inflammatory stimulus
and that this was associated with changes in vascular integrity (56,57). Our studies do not
address the mechanisms by which rates of lymphocyte migration are increased after an
inflammatory stimulus, but do suggest that CD73-generated Ado may trigger a feedback
mechanism to keep increases in permeability under control. Additional experiments with
endothelial cell lines will be required to determine whether Ado receptor signaling modulates
the ability of lymphocytes to migrate across HEV through changes in myosin light chain
phosphorylation and decreased formation of stress fibers and/or through Rap1/Epac mediated
increases in VE-cadherin based cell-cell contacts. Future work will also address the
consequences of increased lymphocyte migration into cd73-/- draining lymph nodes during an
immune response.
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FIGURE 1.
CD73 expression on lymphocytes and HEV. (A) Single cell suspensions of lymph node cells
from cd73+/+ and cd73-/- mice were stained with FITC anti-CD4, FITC anti-CD8, or PE Cy5.5
anti-CD19 plus biotinylated anti-CD73 (TY/23) and PE-streptavidin or the relevant isotype-
matched control antibodies. CD73 expression in cd73+/+ mice is shown in the shaded
histograms and that in cd73-/- mice is shown with solid lines. Staining with isotype control
antibodies is shown with dotted lines. The dotted lines and solid lines are virtually overlapping.
(B) Other lymph nodes from wild type mice were digested with collagenase, DNase I, and
trypsin as described in Materials and Methods and cells were stained with APC anti-CD45,
purified anti-PNAd + Alexa Fluor 488 anti-IgM, and biotinylated anti-CD73 + PE-streptavidin.
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HEV were identified as CD45- PNAd+ cells. (C) Frozen sections of lymph nodes were stained
with anti-CD73 (TY/23) and either anti-PNAd or anti-collagen IV as described in Materials
and Methods. (D) Cd73 and Ado receptor expression were assessed by RT-PCR in a cDNA
library derived from PNAd+ endothelial cells. Representative results are shown from more
than three experiments. (E) Ado receptor expression was assessed by RT-PCR in total wild
type splenocytes. Representative results from more than three experiments are shown.
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FIGURE 2.
Cd73-deficient mice have large draining lymph nodes and high rates of L-selectin-dependent
lymphocyte migration after an inflammatory stimulus LPS (1 μg, A,B,E,F,G,H) or poly(I:C)
(5 μg, C,D) was injected into the left front footpad (or thigh, C,D) of cd73+/+ and cd73-/- mice
and an equivalent volume of PBS was injected into the right front footpad (or thigh, C,D).
Twenty-four h later, the mice were injected with 107 CMFDA-labeled cd73+/+ splenocytes i.v.
One h later, brachial (or inguinal, C,D) lymph nodes were harvested and the total numbers of
cells in each lymph node were counted. (A,C) The lymph node cells were then stained with PE
anti-TCRβ and allophycocyanin anti-B220 (CD45R). The percentages of fluorescent cells were
determined by flow cytometry and the absolute numbers of total lymphoctyes (B,D), T cells
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(E), and B cells (F) that migrated to the lymph nodes in 1 h were calculated. In some
experiments, the mice also received 50 μg anti-L-selectin antibody MEL-14 i.v. at the same
time as LPS/PBS. Twenty-four h later, the mice were injected with 107 CMFDA-labeled
cd73+/+ splenocytes i.v. One h later, lymph nodes were harvested and the total numbers of cells
in each lymph node were counted (G). The percentages of CMFDA+ cells were determined by
flow cytometry and the absolute numbers of total lymphocytes that migrated to the lymph nodes
in 1 h were calculated (H). Data from mice not receiving anti-L-selectin antibody in panels
G and H are the same as in panels A and B. All results are expressed as mean ± SD. and are
representative of 3-10 experiments (n=4 to 5 mice of each genotype for each experiment,
p<0.025 for all comparisons of WT vs. KO in draining lymph nodes in panels A-F, for control
vs. MEL-14 in draining lymph nodes for panel G, and for control vs. MEL-14 in all groups in
panel H).
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FIGURE 3.
CD73 positive and negative lymphocytes migrate equally well into inflamed lymph nodes.
LPS (1 μg) was injected into the left rear footpad of cd73+/+ mice and an equivalent volume
of PBS was injected into the right rear footpad. (A) Twenty-four h later, the popliteal lymph
node cells were stained with FITC anti-CD4, FITC anti-CD8, or PE Cy5.5 anti-CD19 plus
biotinylated anti-CD73 (TY/23) and PE-streptavidin or the relevant isotype-matched control
antibodies and the percentages of CD4+, CD8+, and CD19+ lymphocytes that co-expressed
CD73 were determined by flow cytometry (n=4 in each of two independent experiments).
(B) LPS (1 μg) was injected into the left thigh of cd73+/+ and cd73-/- mice and an equivalent
volume of PBS was injected into the right thigh. Twenty-four h later, the mice were injected
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i.v. with an equal mixture of 1 × 107 cd73+/+ and cd73-/- splenocytes labeled with CMFDA or
CMTMR, respectively. One h later, inguinal lymph nodes were harvested and the percentages
of CMFDA+ and CMTMR+ lymphocytes were determined. Representative data from 1 out of
2 experiments are shown.
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FIGURE 4.
Migration of DC into draining lymph nodes after an inflammatory stimulus. LPS (1 μg) was
injected into the left front footpad of cd73+/+ and cd73-/- mice and an equivalent volume of
PBS was injected into the right front footpad. Six h later, lymph nodes were digested with
collagenase, DNase I, and trypsin as described in Materials and Methods and cells were counted
and stained with FITC anti-MHC Class II and PE anti-CD11c. Dead cells were excluded by
propidium iodide staining. The average (± SEM) absolute numbers of MHC Class IIhi
CD11c+ cells are shown (A) as well as the total number of leukocytes/lymph node (B). The
results are combined from two experiments with a total of nine mice/group. P=0.14 for the
Takedachi et al. Page 20
J Immunol. Author manuscript; available in PMC 2009 July 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
number of MHC Class IIhi CD11c+ cells in draining lymph nodes of wild type vs. cd73-/- mice
and p=0.034 for the comparison of total cell numbers/lymph node.
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FIGURE 5.
CD73 and the A2BAR are up regulated on HEV after an inflammatory stimulus. (A) LPS (1
μg) was injected into the left front footpad of cd73+/+ mice and an equivalent volume of PBS
was injected into the right front footpad. Twenty-four h later, lymph nodes were digested with
collagenase, DNase I, and trypsin as described in Materials and Methods and cells were stained
with APC anti-CD45, purified anti-PNAd + Alexa Fluor 488 anti-IgM, and biotinylated anti-
CD73 + PE-streptavidin. HEV were identified as CD45- PNAd+ cells. The relative mean (MFI)
and median fluorescence intensities for CD73 staining are shown (mean ± S.D., total n= 8 from
3 independent experiments, p<0.01 for MFI and p<0.02 for median fluorescence intensities in
paired t tests comparing PNAd+ cells from inflamed and control lymph nodes). (B) KOP2.16
cells were cultured ± TNFα for 3-6 h. RNA was isolated and A2BAR expression was determined
by semi-quantitative RT-PCR on 5-fold serial dilutions of cDNA using β-actin expression as
in internal standard. Data are representative of 1 out of 2 experiments. Quantitation of the band
intensities revealed a 5-fold increase in A2BAR mRNA at 3 h and a 2.5-fold increase at 6 h
relative to β-actin expression.
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FIGURE 6.
The A2B adenosine receptor agonist, BAY 60-6583, inhibits the increased lymphocyte
migration into draining lymph nodes of CD73-deficient mice. A. LPS (1 μg) was injected into
the left front footpad of cd73+/+ and cd73-/- mice and an equivalent volume of PBS was injected
into the right front footpad. Twenty-two h and 30 min after the LPS injection, the mice were
injected i.v. with BAY 60-6583 (320 μg/kg) or an equivalent volume of diluted PEG 400 carrier
and 30 min later with 107 CMFDA-labeled cd73+/+ splenocytes. One h after the injection of
labeled splenocytes, lymph nodes were harvested and the total numbers of cells in each lymph
node were counted and the percentages of CMFDA+ cells were determined by flow cytometry
(n=20-26, p=0.0034 for diluted PEG 400 vs. BAY 60-6583 in draining lymph nodes, data
combined from 4 separate experiments). B. LPS (1 μg) was injected into the left front footpad
of wild type and cd73-/- mice and an equivalent volume of PBS was injected into the right front
footpad (5 mice/group). Twenty-three h later, the mice were injected i.v. with an equal mixture
of 107 wild type and A2BR-/- splenocytes labeled with CMFDA or CMTMR, respectively. One
h later, brachial lymph nodes were harvested and the percentages of CMFDA+ and
CMTMR+ lymphocytes were determined by flow cytometry. Data are representative of 1 out
of 2 experiments.
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